Megan Filoramo, APRN
Family · Morristown, NJNPI 1003915927
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (34.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Nevro Corp. accounts for 62.2% of it on its own, with 20 other manufacturers making up the rest. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $251.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$33K
- Globus Medical$9K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
- Nalu Medical, Inc.$1K
- SPR Therapeutics, Inc$422
- Medtronic$310
- plus $1K from 15 others
What the payments were for
- Consulting fees$13,74326%
- Speaking & faculty fees$18,57335%
- Travel & lodging$14,92828%
- Food & beverage$6,05911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 125 | $33,155 |
| Globus Medical | 18 | $9,320 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $7,380 |
| Nalu Medical, Inc. | 10 | $1,496 |
| SPR Therapeutics, Inc | 2 | $422 |
| Medtronic | 3 | $310 |
| Saluda Medical Americas, Inc. | 3 | $272 |
| Boston Scientific | 5 | $197 |
| Biotronik NRO, Inc. | 2 | $189 |
| AbbVie | 5 | $169 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $107 |
| E.r. Squibb & Sons, L.L.C. | 1 | $83 |
| Averitas Pharma Inc. | 2 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Abbott | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Pfizer | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Vertex | 1 | $15 |
| Virtus Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$28,307
- XIFAXAN$13,669
- Omnia$12,053
- RELISTOR$6,834
- TRULANCE$6,834
- Nalu Neurostimulation System$1,308
- SPRINT PNS System$422
- Evoke$256
- VANTA ADAPTIVESTIM$200
- Prospera$150
- GENERAL PAIN MANAGEMENT$119
- QULIPTA$112
- UBRELVY$112
How this compares
$53,302 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 74 | $43,514 |
| Xtampza ErOxycodone Myristate | 56 | $37,237 |
| Nurtec OdtRimegepant Sulfate | 11 | $19,412 |
| MovantikNaloxegol Oxalate | 39 | $17,671 |
| Fentanyl | 126 | $16,363 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 487 | $14,028 |
| Buprenorphine | 60 | $6,595 |
| Oxycodone Hcl | 280 | $6,199 |
| Hydromorphone ErHydromorphone Hcl | 18 | $5,922 |
| Gabapentin | 228 | $5,852 |
| ButransBuprenorphine | 11 | $5,774 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 170 | $5,182 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $3,961 |
| Lidocaine | 35 | $3,257 |
| Duloxetine Hcl | 125 | $2,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $29 | $37,23756 claims |
| PfizerNurtec Odt | $17 | $19,41211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Morristown
- Jennifer DemaioMorristown$412K
- Brittany LautherMorristown$20K
- Jenessa DieterleMorristown$15K
- Daniil LibmanMorristown$11K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Shawn DenningToms River$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.